An Open‐Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First‐Line HER2‐Positive Metastatic Breast Cancer

Overview of attention for article published in Oncologist, May 2013

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 4,516 followers.

Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. http://t.co/01fcSJTO51

Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. http://t.co/wi4d1UXaap

Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. http://t.co/krPuI4diEo

Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. http://t.co/MHlpSpp9vR

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.